Wall Street Journal -- After a healthy second quarter, Europe’s pharmaceutical sector may find itself in trouble in the months ahead as companies face patent expiries, tougher regulation and burdensome health care reforms.
Wall Street Journal -- After a healthy second quarter, Europe’s pharmaceutical sector may find itself in trouble in the months ahead as companies face patent expiries, tougher regulation and burdensome health care reforms.
